In 20 adults with type 1 diabetes, investigators evaluated the performance of the Medtrum A8 TouchCare in AID mode over three months.
Findings included more time in range (70-180 mg/dL), increasing from 59.08% to 71.59%. Additionally, investigators saw lower HbA1c, decreasing from 8.13% to 7.61%. Participants also recorded less time in high glucose, with time above range decreased at both levels measured in the study. Investigators saw no hypoglycemia or diabetic ketoacidosis (DKA) among participants as well.
Medtrum concluded that its AID system delivered improved glucose management. The positive findings follow recently announced data backing the system’s Auto Meal Handling, a solution for simplifying mealtime. Instead of calculating carbohydrates, users can log their meal. The AID system responds dynamically to the logging, adjusting insulin delivery based on real-time glucose trends.
TouchCare allows for 24/7 therapy delivery. Users can auto-adjust basal delivery and auto-deliver corrections for high glucose. Users can operate the pump from their smartphone without the need for a separate personal diabetes manager, while the system integrates with Medtrum’s own continuous glucose monitor (CGM) to enable automated delivery. Additionally, users can customize their glucose targets to increase their time in range.
“Further studies with larger and more diverse populations are still needed, but these findings provide encouraging real-world evidence for tubeless automated insulin delivery in everyday diabetes care,” Medtrum said.
